Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review

Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review

Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential therapies for coronavirus disease 2019 (COVID‐19). A thorough understanding of the current body of evidence regarding benefits and r...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Piechotta, V, Iannizzi, C, Chai, KL, Valk, SJ, Kimber, C, Dorando, E, Monsef, I, Wood, EM, Lamikanra, AA, Roberts, DJ, McQuilten, Z, So-Osman, C, Estcourt, LJ, Skoetz, N
Natura:	Journal article
Lingua:	English
Pubblicazione:	Cochrane Collaboration 2021

Documenti analoghi

Hyperimmune immunoglobulin for people with COVID-19
di: Kimber, C, et al.
Pubblicazione: (2021)

Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS‐CoV‐2
di: Valk, SJ, et al.
Pubblicazione: (2021)

A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza
di: Kimber, C, et al.
Pubblicazione: (2022)

The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness
di: So-Osman, C, et al.
Pubblicazione: (2024)

How should we use convalescent plasma therapies for the management of COVID-19?
di: Wood, EM, et al.
Pubblicazione: (2020)

Immunoglobulin replacement to prevent infections in people with haematological malignancies and haematopoietic stem cell transplantation (protocol)
di: Chai, KL, et al.
Pubblicazione: (2024)

SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
di: Hirsch, C, et al.
Pubblicazione: (2021)

The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness
di: Cynthia So-Osman, et al.
Pubblicazione: (2024-09-01)

Methodological challenges for living systematic reviews conducted during the COVID-19 pandemic: A concept paper
di: Iannizzi, C, et al.
Pubblicazione: (2021)

Living systematic reviews in a context of rapidly emerging diseases: challenges and lessons learned
di: Iannizzi, C, et al.
Pubblicazione: (2021)

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
di: Kreuzberger, N, et al.
Pubblicazione: (2021)

Clinical use of convalescent plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities
di: Al-Riyami, AZ, et al.
Pubblicazione: (2020)

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
di: Lorenza Bellusci, et al.
Pubblicazione: (2023-04-01)

Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
di: Massimo Franchini, et al.
Pubblicazione: (2024-02-01)

An update on indications for platelet transfusion
di: Wood, E, et al.
Pubblicazione: (2016)

Development of an ELISA for distinguishing convalescent sera with Mycoplasma hyopneumoniae infection from hyperimmune sera responses to bacterin vaccination in pigs
di: Honglei Ding, et al.
Pubblicazione: (2021-09-01)

Extension of the PRISMA 2020 statement for living systematic reviews (LSRs): protocol [version 2; peer review: 2 approved]
di: Lara A Kahale, et al.
Pubblicazione: (2022-06-01)

Extension of the PRISMA 2020 statement for living systematic reviews (LSRs): protocol [version 1; peer review: 2 approved]
di: Lara A Kahale, et al.
Pubblicazione: (2022-01-01)

Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza
di: Hillary A. Vanderven, et al.
Pubblicazione: (2023-07-01)

Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation
di: Majno Pietro, et al.
Pubblicazione: (2010-07-01)

Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants
di: Zhuoming Liu, et al.
Pubblicazione: (2022-04-01)

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: A network meta‐analysis
di: Piechotta, V, et al.
Pubblicazione: (2019)

The production of hyperimmune pseudotuberculosis sera
di: T. Yu. Zagoskina, et al.
Pubblicazione: (2021-08-01)

Competing events and in-hospital follow-up: issues to be aware of
di: Sandercock, J, et al.
Pubblicazione: (2023)

Diagnosis of Bactec samples by immunoglobulins of mouse hyperimmune sera obtained against modified antigens of the cell wall of Mycobacterium tuberculosis
di: I. V. Kozlova, et al.
Pubblicazione: (2019-11-01)

The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19
di: Daniele Focosi, et al.
Pubblicazione: (2021-02-01)

Convalescent plasma for Covid-19 - making sense of the inconsistencies
di: Estcourt, L, et al.
Pubblicazione: (2022)

Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review
di: Vanessa Piechotta, et al.
Pubblicazione: (2022-05-01)

Hyperimmune Globulins for the Management of Infectious Diseases
di: Ilaria Pati, et al.
Pubblicazione: (2023-07-01)

Development of an indirect ELISA for detecting humoral immunodominant proteins of Mycoplasma hyopneumoniae which can discriminate between inactivated bacterin-induced hyperimmune sera and convalescent sera
di: Honglei Ding, et al.
Pubblicazione: (2019-09-01)

The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial
di: Estcourt, L, et al.
Pubblicazione: (2019)

Method of obtaining and storing hyperimmune anthrax serum
di: S. V. Ivanova, et al.
Pubblicazione: (2023-09-01)

A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation (Russian Translation of Cochrane Plain Language Summary)
di: Crighton, GL, et al.
Pubblicazione: (2021)

Dynamics of clinical symptoms and secretory immunoglobulin a in COVID-19 convalescent patients
di: Albina А. Khasanova, et al.
Pubblicazione: (2022-12-01)

Methods and guidance on conducting, reporting, publishing, and appraising living systematic reviews: a scoping review
di: Claire Iannizzi, et al.
Pubblicazione: (2023-12-01)

Effect of convalescent plasma on organ support-free days in critically ill patients With COVID-19: a randomized clinical trial
di: Estcourt, LJ, et al.
Pubblicazione: (2021)

Effects of SARS-CoV-2 strain variation on virus neutralisation titres: therapeutic use of convalescent plasma
di: Nguyen, D, et al.
Pubblicazione: (2021)

Preparation of Hyperimmune Sera to Thermoextracts of Brucella S- and L-Forms
di: L. M. Мikhailov, et al.
Pubblicazione: (2016-12-01)

Prevention and treatment of influenza with hyperimmune bovine colostrum antibody.
di: Wy Ching Ng, et al.
Pubblicazione: (2010-01-01)

Hyperimmune egg: preparation, characterization and alternative immunotherapeutic activity
di: Teodora Supeanu, et al.
Pubblicazione: (2019-05-01)